| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
COMT targets catecholamines including adrenaline, noradrenaline, and dopamine. It is used to regulate epinephrine, norepinephrine, and dopamine levels in the brain. Its "target" in research is the catecholamine metabolic pathway and the regulation of neurotransmitter levels.
|
|---|---|
| ln Vitro |
In vitro, COMT activity is measured by its ability to methylate catechol substrates using S-adenosyl-L-methionine as the methyl donor. The enzyme acts more rapidly on catecholamines such as adrenaline or noradrenaline than on catechols. Its activity is studied in cell-free systems using purified enzyme or tissue homogenates.
|
| ln Vivo |
In vivo, COMT regulates epinephrine, norepinephrine, and dopamine levels in the brain. It is involved in the metabolism of catecholamine neurotransmitters and plays a role in various physiological processes including mood regulation, cognition, and cardiovascular function. Its activity is studied in the context of neurological and psychiatric disorders.
|
| Enzyme Assay |
In vitro enzyme assays for COMT typically involve incubating the enzyme with a catechol substrate (e.g., adrenaline, noradrenaline, or dopamine) and S-adenosyl-L-methionine as the methyl donor. The reaction is carried out in appropriate buffer at physiological pH and temperature. The methylated product is quantified by HPLC, radiometric methods, or mass spectrometry.
|
| Cell Assay |
COMT is not typically used in cell culture experiments as a compound to treat cells. However, its activity can be measured in cell lysates or tissue homogenates from cultured cells. Cells are cultured, harvested, and lysed, and COMT activity is measured using standard enzyme assays. Inhibitors or modulators of COMT can be tested in these systems.
|
| Animal Protocol |
In vivo animal experiments with COMT typically involve measuring its activity in brain tissue or other organs. Animal models of neurological or psychiatric disorders are used to study changes in COMT activity and their correlation with disease states. COMT inhibitors are also tested in animal models to evaluate their effects on neurotransmitter levels and behavior.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of COMT are not applicable as it is an enzyme, not a therapeutic agent. As a protein, it is not administered as a drug. Its activity and stability are characterized in vitro under controlled conditions. The mammalian enzyme acts more rapidly on catecholamines than on catechols.
|
| Toxicity/Toxicokinetics |
COMT is handled as a laboratory reagent. It may cause allergic reactions in sensitive individuals. Standard laboratory safety practices, including the use of gloves and eye protection, should be followed when handling. It is not classified as a highly hazardous substance. It is typically stored at appropriate conditions to maintain enzymatic activity.
|
| References | |
| Additional Infomation |
COMT (Catechol O-methyltransferase) is an enzyme that catalyzes the methylation of catechol substrates using S-adenosyl-L-methionine. It exists in soluble and membrane-bound forms and regulates epinephrine, norepinephrine, and dopamine levels in the brain. It acts more rapidly on catecholamines than on catechols. The enzyme is not a drug and has no therapeutic indications. It is available for laboratory research use only.
|
| Exact Mass |
636.496
|
|---|---|
| CAS # |
9012-25-3
|
| PubChem CID |
74319293
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
771.4±40.0 °C at 760 mmHg
|
| Flash Point |
227.5±20.8 °C
|
| Vapour Pressure |
0.0±6.0 mmHg at 25°C
|
| Index of Refraction |
1.507
|
| LogP |
7.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
582
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2CCC(C)=CCCC(C)=CC=C(C(C)C)CC(C12C)OC(C)=O
|
| InChi Key |
DGDSKYGEKMVUCF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H34O3/c1-15(2)19-12-10-16(3)8-7-9-17(4)11-13-20-22(6,25-20)21(14-19)24-18(5)23/h9-10,12,15,20-21H,7-8,11,13-14H2,1-6H3
|
| Chemical Name |
(1,7,11-trimethyl-4-propan-2-yl-15-oxabicyclo[12.1.0]pentadeca-4,6,10-trien-2-yl) acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
